<DOC>
	<DOC>NCT02173171</DOC>
	<brief_summary>A Registry Study to Evaluate the Survival and Long-Term Safety of Subjects With Melanoma Who Previously Received Talimogene Laherparepvec</brief_summary>
	<brief_title>Registry Study for Talimogene Laherparepvec</brief_title>
	<detailed_description>A Registry Study to Evaluate the Survival and Long-Term Safety of Subjects With Melanoma Who Previously Received at least 1 dose of Talimogene Laherparepvec. FU will occur q3m.</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<criteria>All subjects must provide informed consent prior to initiation of any study activities. All subjects must have received at least one dose of talimogene laherparepvec on an Amgen or BioVEXsponsored clinical trial and must have permanently discontinued treatment on that trial. Subjects currently receiving or planning to receive talimogene laherparepvec in the next 30 days.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Melanoma</keyword>
</DOC>